Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death

about

Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death

Item

http://www.wikidata.org/entity/Q57074270

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Development of a risk grading ...... ia at high risk of early death

@en

Development of a risk grading ...... ia at high risk of early death

@nl

type

Item

label

Development of a risk grading ...... ia at high risk of early death

@en

Development of a risk grading ...... ia at high risk of early death

@nl

prefLabel

Development of a risk grading ...... ia at high risk of early death

@en

Development of a risk grading ...... ia at high risk of early death

@nl

P1476

Development of a risk grading ...... ia at high risk of early death

@en

P2093

Bo Jin

http://www.w3.org/2001/XMLSchema#string

Fei Ge

http://www.w3.org/2001/XMLSchema#string

Fenglin Cao

http://www.w3.org/2001/XMLSchema#string

Haitao Li

http://www.w3.org/2001/XMLSchema#string

Hongli Zhao

http://www.w3.org/2001/XMLSchema#string

HuiyuanYang

http://www.w3.org/2001/XMLSchema#string

Jiayue Sun

http://www.w3.org/2001/XMLSchema#string

Jin Zhou

http://www.w3.org/2001/XMLSchema#string

Jinxiao Hou

http://www.w3.org/2001/XMLSchema#string

Jinyue Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center Study

P304

3619-3627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S167686

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30271210

http://www.w3.org/2001/XMLSchema#string

P932

6149832

http://www.w3.org/2001/XMLSchema#string